The heparins: All a nephrologist should know

Nephrology Dialysis Transplantation

Volumn 20, Issue 10, 2005, Pages 2036-2042

  Hetzel, Gerd R ^a   Sucker, Christoph ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; CERTOPARIN; DALTEPARIN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NAFAMSTAT; REVIPARIN; TINZAPARIN;

ANAPHYLAXIS; ANTICOAGULATION; BLEEDING; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG USE; EDITORIAL; FRACTURE; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IN VIVO STUDY; KIDNEY FAILURE; META ANALYSIS; NONHUMAN; OSTEOPOROSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS;

ANTICOAGULANTS; HEPARIN; HUMANS; KIDNEY FAILURE; MOLECULAR STRUCTURE; PLATELET FACTOR 4; RISK FACTORS; THROMBOCYTOPENIA;

EID: 27144473460     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi004     Document Type: Editorial

References (64)

1. Cohen M, Demers C, Gurfinkel EP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-452
2. Antman EM, Cohen M, Radley D et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602-1608
3. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-809
4. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF. Enoxaparin and bleeding complications: A review in patients with and without renal insufficiency. Pharmacotherapy 2000; 20: 771-775
5. Busby LT, Weyman A, Rodgers GM. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol 2001; 67: 54-56
6. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146: 33-41
7. Shullo MA, Rose ML, Vivas C et al. Hemorrhagic complications of enoxaparin and aspirin in patients with kidney transplants. Pharmacotherapy 2002; 22: 184-187
8. Farooq V, Hegarty J, Chandrasekar T et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 2004; 43: 531-537
9. Haase M, Bellomo R, Rocktaeschel J et al. Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II. Nephrol Dial Transplant 2005; 20: 444-446
10. Kaiser B, Hoppensteadt DA, Fareed J. Tissue factor pathway inhibitor: An update of potential implications in the treatment of cardiovascular disorders. Expert Opin Investig Drugs 2001; 10: 1925-1935
11. McLean J. The thromboplastic action of cephalin. Am J Physiol 1916; 41: 250-257
12. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy Ann Intern Med 1993; 119: 104-109
13. Olson JD, Arkin CF, Brandt JT et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122: 782-798
14. Raschke R, Hirsh J, Guidry JR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med 2003; 138: 720-723
15. Magee KD, Sevcik W, Moher D, Rowe BH. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes. Cochrane Database Syst Rev 2003; (1): CD002132
16. Ljungberg B, Jacobson SH, Lins LE, Pejler G. Effective anticoagulation by a low molecular weight heparin (Fragmin) in hemodialysis with a highly permeable polysulfone membrane. Clin Nephrol 1992; 38: 97-100
17. Sagedal S, Hartmann A, Sundstrom K, Bjornsen S, Fauchald P, Brosstad F. A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrol Dial Transplant 1999; 14: 1943-1947
18. Klingel R, Schwarting A, Lotz J, Eckert M, Hohmann V, Hafner G. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study. Kidney Blood Press Res 2004; 27: 211-217
19. Guillet B, Simon N, Sampol JJ et al. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant 2003; 18: 2348-2353
20. Baumelou A, Singlas E, Petitclerc T, Desmichels D, Jacobs C, Soria J. Pharmacokinetics of a low molecular weight heparin (reviparine) in hemodialyzed patients. Nephron 1994; 68: 202-206
21. Hainer JW, Sherrard DJ, Swan SK et al. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. Am J Kidney Dis 2002; 40: 531-538
22. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: A meta-analysis of randomized trials. J Am Soc Nephrol 2004; 15: 3192-3206
23. Goudable C, Saivin S, Houin G et al. Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. Nephron 1991; 59: 543-545
24. Cadroy Y, Pourrat J, Baladre MF et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991; 63: 385-390
25. Becker RC, Spencer FA, Gibson M. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002; 143: 753-759
26. Mismetti P, Laporte-Simitsidis S, Navarro C et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemostasis 1998; 79: 1162-1165
27. Siguret V, Pautas E, Fevrier M et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemostasis 2000; 84: 800-804
28. Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002; 25: 725-733
29. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002; 162: 2605-2609
30. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78: 2337-2343
31. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: On behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemostasis 2002; 87: 163-164
32. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122: 799-807
33. Kruse MW, Lee JJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J 2004; 148: 582-589
34. Frank RD, Brandenburg VM, Lanzmich R, Floege J. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis. Nephrol Dial Transplant 2004; 19: 1552-1558
35. Crowther MA, Berry LR, Monagle PT, Chan AK. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002; 116: 178-186
36. Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002; 105: 225-231
37. Nelson-Piercy C. Hazards of heparin: Allergy, heparininduced thrombocytopenia and osteoporosis. Baillieres Clin Obstet Gynaecol 1997; 11: 489-509
38. Greer IA. Exploring the role of low-molecular-weight heparins in pregnancy. Semin Thromb Hemostasis 2002; 28 [Suppl 3]: 25-31
39. Barbour LA, Kick SD, Steiner JF et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994; 170: 862-869
40. Douketis JD, Ginsberg JS, Burrows RF et al. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemostasis 1996; 75: 254-257
41. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168: 1265-1270
42. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemostasis 1994; 71: 7-11
43. Shefras J, Farquharson RG. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol 1996; 65: 171-174
44. Pettilä V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res 1999; 96: 275-282
45. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703-1708
46. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005; 127: 35S-45S
47. Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 1996; 28: 82-85
48. Greinacher A, Zinn S, Wizemann, Birk UW. Heparin-induced antibodies as a risk factor for thromboembolism and haemorrhage in patients undergoing chronic haemodialysis. Lancet 1996; 348: 764
49. Sitter T, Spannagl M, Banas B, Schiffl H. Prevalence of heparin-induced PF4-heparin antibodies in hemodialysis patients. Nephron 1998; 79: 245-246
50. Luzzatto G, Bertoli M, Cella G, Fabris F, Zaia B, Girolami A. Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis. Thromb Res 1998; 89: 115-122
51. O'Shea SI, Sands JJ, Nudo SA, Ortel TL. Frequency of antiheparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. Am J Hematol 2002; 69: 72-73
52. Mureebe L, Coats RD, Silliman WR, Shuster TA, Nichols WK, Silver D. Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients. Surgery 2004; 136: 848-853
53. Amiral J, Bridey F, Wolf M et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb Haemostasis 1995; 73: 21-28
54. Koster A, Meyer O, Hausmann H, Kuppe H, Hetzer R, Mertzlufft F. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II under-going cardiovascular surgery. J Clin Anesth 2000; 12: 324-327
55. Magnani HN. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia. Platelets 1997; 8: 74-81
56. Henny CP, ten Cate H, Surachno S et al. The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis. Thromb Haemostasis 1985; 54: 460-462
57. Polkinghorne KR, McMahon LP, Becker GJ. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 2002; 40: 990-995
58. Fischer KG. Hirudin in renal insufficiency. Semin Thromb Hemostasis 2002; 28: 467-482
59. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003; 10: 2062-2065
60. Okada H, Moriwaki K, Nakamoto H, Sugahara S, Suzuki H. Positive skin reaction test in haemodialysis patients allergic to nafamostat mesilate. Nephrol Dial Transplant 1998; 13: 2166-2167
61. Higuchi N, Yamazaki H, Kikuchi H, Gejyo F. Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesilate, following nine administrations in a hemodialysis patient. Nephron 2000; 86: 400-401
62. Boneu B, Necciari J, Cariou R et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemostasis 1995; 74: 1468-1473
63. Murray PT, Reddy BV, Grossman EJ et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 2004; 66: 2446-2453
64. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-329